Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes.

ABSTRACT:

Background

To stop the spread of the COVID-19 disease, it is crucial to create molecular tools to investigate and diagnose COVID-19. Current efforts focus on developing specific neutralizing monoclonal antibodies (NmAbs) elicited against the receptor-binding domain (RBD).

Methods

In the present study, recombinant RBD (rRBD) protein was produced in E. coli, followed by immunizing mice with purified rRBD. ELISA was applied to screen the hybridomas for positive reactivity with rRBD protein. The linear and conformational epitopes of the mAbs were subsequently identified using western blot. Finally, the reactivity, affinity, and neutralization activity of the purified mAbs were evaluated using ELISA.

Results

All mAbs exhibited similar reactivity trends towards both eukaryo

SUBMITTER: Zadeh SMM 

PROVIDER: S-EPMC10845636 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature